Pre-clinical data suggests Noxopharm’s anti-cancer drug can boost radiation effect on paediatric bra
- OPACC
- Jul 6, 2018
- 1 min read
Pre-clinical data has confirmed Noxopharm’s (ASX: NOX) experimental idronoxil anti-cancer drug can boost the killing effect of radiation when treating paediatric brain cancer cells.
Comments